AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
GlobalData on MSN13d
Leveragen and Moonlight Bio unite for T-cell therapy developmentLeveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
Korean researchers develop Trojan horse method to produce antibodies in tumors Innovative nanoparticle platform creates tumor ...
Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...
AbbVie and Xilio Therapeutics have inked a collaboration and option-to-license agreement potentially worth more than $2 billion to clinical-stage biotechnology company Xilio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback